Jones S J, Dicker A J, Dahler A L, Saunders N A
Centre for Immunology and Cancer Research, University of Queensland Department of Medicine, Princess Alexandra Hospital, Woolloonggabba, Australia.
J Invest Dermatol. 1997 Aug;109(2):187-93. doi: 10.1111/1523-1747.ep12319308.
E2F and DP family members are established regulators of the cell cycle. In this study, we examined their activity/expression during keratinocyte growth arrest. Treating human epidermal keratinocytes with the growth inhibitors TPA or IFN-gamma or allowing the cells to reach confluence resulted in 90% inhibition of DNA synthesis, whereas a keratinocyte-derived squamous carcinoma cell line (SCC25) was resistant to growth inhibitors. Gel shift analysis of keratinocytes using an E2F response element indicated that growth arrest was associated with a decrease in all E2F binding complexes. This indicates that growth inhibition is not due to negative regulation by pocket proteins. Conversely, gel shift analysis of growth inhibitor-resistant SCC25 cells showed no decrease in E2F binding. If deregulated E2F expression/activity is involved in tumor development, then the deliberate deregulation of E2F activity may make keratinocytes resistant to growth inhibitors in much the same way as the SCC cells. The HPV16 E7 protein is known to activate E2F. Retroviral infection of keratinocytes with E7-expressing constructs resulted in growth inhibitor resistance, whereas infection with E6 constructs did not. E2F is a heterodimeric complex consisting of E2F family members (1-5) and DP proteins (1-3). Examination of the expression levels for E2F genes and other genes associated with the cell cycle indicated that E2F1 was profoundly decreased in growth-arrested keratinocytes (90%), whereas E2F3, E2F5, and DP1 were not. E2F2 and E2F4 were increased in IFN-gamma-treated keratinocytes but not in TPA-treated or confluent keratinocytes. In contrast, SCC25 cells did not undergo growth arrest and did not downregulate E2F1 mRNA expression in response to growth inhibitors. Our results indicate that E2F DNA binding and in particular E2F1 mRNA expression are associated with keratinocyte proliferation. Our results with the SCC25 cells and the E7-infected cells are consistent with the proposition that deregulated E2F expression/activity (in particular E2F1) may be involved in the unregulated proliferation of skin tumor cells.
E2F和DP家族成员是公认的细胞周期调节因子。在本研究中,我们检测了它们在角质形成细胞生长停滞期间的活性/表达情况。用生长抑制剂佛波酯(TPA)或γ干扰素(IFN-γ)处理人表皮角质形成细胞,或让细胞达到汇合状态,均导致DNA合成受到90%的抑制,而一种源自角质形成细胞的鳞状癌细胞系(SCC25)对生长抑制剂具有抗性。使用E2F反应元件对角质形成细胞进行凝胶迁移分析表明,生长停滞与所有E2F结合复合物的减少有关。这表明生长抑制并非由于口袋蛋白的负调控所致。相反,对生长抑制剂抗性的SCC25细胞进行凝胶迁移分析显示,E2F结合没有减少。如果E2F表达/活性失调参与肿瘤发生,那么故意使E2F活性失调可能会使角质形成细胞对生长抑制剂产生抗性,其方式与SCC细胞大致相同。已知人乳头瘤病毒16型(HPV16)E7蛋白可激活E2F。用表达E7的构建体对角质形成细胞进行逆转录病毒感染导致对生长抑制剂产生抗性,而用E6构建体感染则没有这种效果。E2F是一种异二聚体复合物,由E2F家族成员(1 - 5)和DP蛋白(1 - 3)组成。检测E2F基因和其他与细胞周期相关基因的表达水平表明,在生长停滞的角质形成细胞中E2F1显著降低(90%),而E2F3、E2F5和DP1则没有。E2F2和E2F4在IFN-γ处理的角质形成细胞中增加,但在TPA处理或汇合的角质形成细胞中没有增加。相比之下,SCC25细胞没有经历生长停滞,并且在对生长抑制剂的反应中没有下调E2F1 mRNA表达。我们的结果表明,E2F与DNA的结合,特别是E2F1 mRNA的表达与角质形成细胞的增殖有关。我们对SCC25细胞和E7感染细胞的研究结果与以下观点一致,即E2F表达/活性失调(特别是E2F1)可能参与皮肤肿瘤细胞的失控增殖。